Phase 1 N=10 ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants
Phase 1 N=22 Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
Dengue
Primary: Systemic and Local Reactogenicity Rates for Ungraded Symptoms — 0; 1; 0; 2 Participants
Phase 2 N=192 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Dengue
Primary: Percentage of Study Participants With Each Solicited, Related Adverse Event Types of Any Severity. — 1; 0; 1; 0 Participants
Phase 2 N=360 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
Healthy
Primary: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination Dose by Severity — 7; 0; 14; 3 participants
Phase 2 N=7 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
Dengue Fever
Primary: Number of Solicited Adverse Events Within 21 Days After the First Dose of Dengue Vaccine. — 1; 3; 5; 3 adverse events
Phase 2 N=29 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15 — 58.9; 15325.2; 5510.0; 11.2 titer
Phase 2 N=51 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
Dengue
Primary: Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine. — 3; 1; 11; 1 specified events
Phase 2 N=120 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand
Dengue
Primary: Incidence of Any Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1 — 0.0; 0.0; 0.0; 0.0 percentage of subjects
Phase 3 N=20,099 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
Healthy Volunteers
Primary: Vaccine Efficacy (VE) of Two Doses of Tetravalent Dengue Vaccine Candidate (TDV) in Preventing Virologically-Confirmed Dengue Fever Induced by Any Dengue Serotype — 149…
Phase 2 N=189 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Virus Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or…
Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
Phase 3 N=480 A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
Healthy Volunteers
Primary: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years…
Phase 2 N=56 An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
Dengue
Primary: Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. — 3.00; 5.2; 4.7; 5.0 log10 RNA copies/mL/days
Phase 2 N=86 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
Dengue
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 7; 2; 4; 5 Participants
N/A N=2,116 Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
Dengue
Primary: Incidence of All Laboratory-confirmed Symptomatic Dengue Infection — 10.5; 11.5 Cases in 1000 person-years
Phase 2 N=180 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain Before and Following Injection (Inj.) With CYD Dengue Tetravalent…
Phase 1 N=42 A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 0 Participants
Phase 1 N=100 A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
Dengue Fever
Primary: Number of Subjects With Adverse Events Within the 28 Day Follow-up — 10; 9; 10; 14 Participants
N/A N=2,004 A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
Dengue
Primary: Incidence Rate of Acute Febrile Illness (AFI) Due to Laboratory Confirmed Dengue (LCD) Overall, and by Age Group — 21.25; 22.69; 12.76; 9.16 Person-year rate ( Per 1000)
Phase 2 N=86 Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
Dengue
Primary: N Antibody, Geometric Mean Titer(GMT) to Dengue Serotypes 1, 2, 3 and 4 — 2; 2; 2; 13 GMT value
Phase 2 N=200 Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
Healthy Volunteers
Primary: Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination — 97.1 percentage of…
Phase 2 N=390 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 — 5.38…
Phase 3 N=900 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
Dengue
Primary: Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization…
Phase 3 N=10,275 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD…
Phase 1 N=140 A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
Healthy
Primary: Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported — 25; 25; 24; 21 participants
Phase 3 N=20,869 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Dengue Fever · Dengue Hemorrhagic Fever · Dengue
Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue…
Phase 2 N=4,002 Efficacy and Safety of Dengue Vaccine in Healthy Children
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo — 45; 32…
Phase 3 N=200 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 — 557.4; 2047.4; 131.8; 119.6 titer
Phase 3 N=923 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
Dengue Fever
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset — 5.3; 202.9; 293.8; 322.1 titer